Healthy Nevada Project Sharing Clinical Results with Consenting Participants
October 02, 2018 08:00 ET | Renown Health
Reno, Nev., Oct. 02, 2018 (GLOBE NEWSWIRE) -- The Healthy Nevada Project led by Renown Institute for Health Innovation (Renown IHI) is announcing another landmark milestone – returning clinical...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
September 10, 2018 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
ProLynx announces allowance of additional U.S. patent for PLX038, a novel DNA damage response enhancer
April 10, 2018 09:00 ET | ProLynx LLC
SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Prolynx LLC (San Francisco, CA) announced it received a Notice of Allowance for its DNA damage enhancer PLX038 (PEG~SN-38), currently in Phase 1...
Cyclacel Pharmaceuticals logo
Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO
June 06, 2016 10:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., June 06, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), reported today updated Phase 1 data from its DNA...
BRCA Gene Testing-Based Breast Cancer and Ovarian Cancer Keynote Speaker, Advocate, Advisor and 'Previvor' Launches 'BRCA Believer' Brand Inspired by Personal Experience
July 22, 2014 14:23 ET | BRCA Believer
SAN DIEGO, CA--(Marketwired - July 22, 2014) - BRCA gene testing-based breast cancer and ovarian cancer keynote speaker, advocate, advisor and "previvor," Merilee Kern, today announced the launch of...
CONTEMPORARY OBSTETRICS AND GYNECOLOGY OF DAYTON ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
September 30, 2013 10:34 ET | Genetic Technologies Group
DAYTON, Ohio, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Contemporary Obstetrics & Gynecology, part of the Providence Medical Group, today announced the availability of the BREVAGen™ predictive risk...
PEARL W. YEE, M.D. INC. OF SAN FRANCISCO ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
September 16, 2013 10:08 ET | Genetic Technologies Group
SAN FRANCISCO, Sept. 16, 2013 (GLOBE NEWSWIRE) -- Pearl Yee, MD, FACOG and clinical professor at the University of California, San Francisco, is pleased to announce that her private practice, Pearl W....
OB/GYN ASSOCIATES IN LEWISBURG, PA ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
August 26, 2013 13:06 ET | Genetic Technologies Group
SUNBURY, PA., Aug. 26, 2013 (GLOBE NEWSWIRE) -- Russell Stankiewicz, MD, FACOG, CCD, NMCP, is pleased to announce that OB/GYN Associates of Lewisburg, P.C. in Lewisburg, PA is now offering the...
THE HEWITT CENTER FOR BREAST WELLNESS AT GRIFFIN HOSPITAL IN DERBY, CT LAUNCHES HIGH-RISK PROGRAM INCLUDING STATE-OF-THE-ART BREAST CANCER SCREENING OPTIONS
June 24, 2013 12:16 ET | Genetic Technologies Group
DERBY, Conn., June 24, 2013 (GLOBE NEWSWIRE) -- Denise Barajas, MD, medical director at The Hewitt Center for Breast Wellness in Derby, CT, has launched a high-risk breast cancer program that includes...
Atossa Genetics to Sponsor Screenings of Decoding Annie Parker at the Seattle International Film Festival on June 6 and 8, 2013
May 21, 2013 08:30 ET | Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - May 21, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is sponsoring two screenings of the new film Decoding Annie Parker at the Seattle...